Medtronic's Yin gives advice on China; Sucampo in Amitiza license deal with China's Harbin Gloria;

> Medtronic ($MDT) China Regulatory Director Annie Yin offered some homespun advice on working in China. Report

> India's drug price regulator has capped prices of 30 medicines including antibiotics and treatments for diabetes, tuberculosis and malaria. Report

> Specialised Therapeutics Australia and Swiss-based Helsinn said the Therapeutic Goods Administration has approved AKYNZEO, used to treat nausea associated with cancer chemotherapy. Release

> Sinovac ($SVA) filed a form 20-F with the U.S. SEC detailing outlook. Document

> Hong Kong-listed Golden Meditech Holdings entered into an agreement with Magnum Opus International to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of $25 million. Release (PDF)

> Santen Pharmaceutical Co. has entered into an agreement with Showa Yakuhin Kako Co. and Hyperion Pharma Co. to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan. Release

> Takeda Pharmaceutical said that the first patient has been enrolled in the Phase III TOURMALINE-MM4 study of investigational oral ixazomib. Release

> Sucampo Pharmaceuticals has entered into an exclusive license, development, commercialization and supply agreement with China's Harbin Gloria Pharmaceuticals to have it develop and commercialize Amitiza in China. Release

> India's Pharmaceuticals Export Promotion Council says drug exports increased at a slower pace this past fiscal year to $15.2 billion. Report

> The Comptroller and Auditor General of India counted 36 cases amounting to $21 billion in which drugmakers violated the law by claiming gifts and favors to physicians as deductible expenses. Report